Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

British Columbia hospitals get $423m for major upgrades, expansion:

This article was originally published in Clinica

Executive Summary

Three British Columbia hospitals have had capital funding approved for major upgrade work, totalling Can$469m (US$423m). The largest of the three public-private investments is Can$269 for a new 320,000 square foot, 500-bed acute care facility, to replace the bulk of inpatient acitivity at the Royal Jubilee Hospital in Victoria. This initial funding will be jointly contributed by the provincial government (Can$150m), the Capital Regional Hospital District (Can$100m) and the Vancouver Island Health Authority (Can$19m). The Kelowna General Hospital will receive Can$119m to build a new outpatient hospital and to "quadruple" the size of its emergency department. Can$81m has been approved to provide a new diagnostic and treatment building for the Vernon Jubilee Hospital, an acute care facility.

You may also be interested in...



Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar

Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel